January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Ultragenyx Pharmaceutical is a mid-cap biotech firm with a promising pipeline and an optimistic outlook from analysts. Click ...

Sanders was Congress's second-largest recipient of pharmaceutical donations in 2016 yet received only individual donations ...